Clinical trial / 2019
Resveratrol supplementation for 4 weeks significantly reduced serum IL6 levels within the intervention group, but showed no differences between groups.
In this randomized clinical trial, 43 patients with type 2 diabetes and chronic periodontitis were randomly allocated to receive resveratrol supplements or placebo for 4 weeks alongside non-surgical periodontal therapy. In the intervention group, the mean serum level of IL6 decreased significantly post-intervention from 2.19 ± 1.09 to 1.58 ± 1.06 (P = 0.039). However, no significant differences were observed between the intervention and control groups post-intervention for IL6, TNFα, TAC, or CAL.
- Study type
- Randomized clinical trial
- Who was studied
- 43 patients with type 2 diabetes and chronic periodontitis
- What was measured
- Serum levels of IL6, TNFα, TAC, and clinical attachment loss (CAL)
THE PAPER
Impact of resveratrol supplementation on inflammatory, antioxidant, and periodontal markers in type 2 diabetic patients with chronic periodontitis.
Javid AZ, Hormoznejad R, Yousefimanesh HA, Haghighi-Zadeh MH, Zakerkish M. Diabetes Metab Syndr, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.